Cargando…
The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination
Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of mousepox), encode immune response...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292233/ https://www.ncbi.nlm.nih.gov/pubmed/18391063 http://dx.doi.org/10.1084/jem.20071854 |
_version_ | 1782152490390650880 |
---|---|
author | Xu, Ren-Huan Cohen, Matthew Tang, Yong Lazear, Eric Whitbeck, J. Charles Eisenberg, Roselyn J. Cohen, Gary H. Sigal, Luis J. |
author_facet | Xu, Ren-Huan Cohen, Matthew Tang, Yong Lazear, Eric Whitbeck, J. Charles Eisenberg, Roselyn J. Cohen, Gary H. Sigal, Luis J. |
author_sort | Xu, Ren-Huan |
collection | PubMed |
description | Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of mousepox), encode immune response modifiers (IRMs) that can increase virulence by decreasing the host immune response. We show that one of these IRMs, the type I interferon (IFN) binding protein (bp) of ECTV, is essential for ECTV virulence and is a natural target of the antibody response. More strikingly, we demonstrate that immunization with recombinant type I IFN bp protects mice from lethal mousepox. Collectively, our experiments have important implications for our understanding of the role of IRMs in OPV virulence and of type I IFNs in OPV infections. Furthermore, our work provides proof of concept that effective antiviral vaccines can be made to prevent disease by targeting virulence factors as an alternative to the traditional approach that attempts to prevent infection by virus neutralization. |
format | Text |
id | pubmed-2292233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22922332008-10-14 The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination Xu, Ren-Huan Cohen, Matthew Tang, Yong Lazear, Eric Whitbeck, J. Charles Eisenberg, Roselyn J. Cohen, Gary H. Sigal, Luis J. J Exp Med Articles Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of mousepox), encode immune response modifiers (IRMs) that can increase virulence by decreasing the host immune response. We show that one of these IRMs, the type I interferon (IFN) binding protein (bp) of ECTV, is essential for ECTV virulence and is a natural target of the antibody response. More strikingly, we demonstrate that immunization with recombinant type I IFN bp protects mice from lethal mousepox. Collectively, our experiments have important implications for our understanding of the role of IRMs in OPV virulence and of type I IFNs in OPV infections. Furthermore, our work provides proof of concept that effective antiviral vaccines can be made to prevent disease by targeting virulence factors as an alternative to the traditional approach that attempts to prevent infection by virus neutralization. The Rockefeller University Press 2008-04-14 /pmc/articles/PMC2292233/ /pubmed/18391063 http://dx.doi.org/10.1084/jem.20071854 Text en Copyright © 2008, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Xu, Ren-Huan Cohen, Matthew Tang, Yong Lazear, Eric Whitbeck, J. Charles Eisenberg, Roselyn J. Cohen, Gary H. Sigal, Luis J. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title | The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title_full | The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title_fullStr | The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title_full_unstemmed | The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title_short | The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination |
title_sort | orthopoxvirus type i ifn binding protein is essential for virulence and an effective target for vaccination |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292233/ https://www.ncbi.nlm.nih.gov/pubmed/18391063 http://dx.doi.org/10.1084/jem.20071854 |
work_keys_str_mv | AT xurenhuan theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT cohenmatthew theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT tangyong theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT lazeareric theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT whitbeckjcharles theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT eisenbergroselynj theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT cohengaryh theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT sigalluisj theorthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT xurenhuan orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT cohenmatthew orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT tangyong orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT lazeareric orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT whitbeckjcharles orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT eisenbergroselynj orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT cohengaryh orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination AT sigalluisj orthopoxvirustypeiifnbindingproteinisessentialforvirulenceandaneffectivetargetforvaccination |